Can Eptinezumab reduce migraine severity in cases unresponsive to other treatments?

Hello,

Welcome to icliniq.com.

I understand your concern. Eptinezumab is a relatively new migraine treatment administered through a series of infusions. It belongs to the calcitonin gene-related peptide (CGRP) inhibitor class, which blocks the activity of CGRP, a protein associated with the inflammatory response in migraines. Studies indicate that Eptinezumab significantly reduces migraine frequency and severity in patients unresponsive to other treatments. In clinical trials, those receiving Eptinezumab had an average of 7.4 fewer migraine days per month than those on a placebo.

The treatment consists of four infusions, each lasting 30 minutes. The initial infusion is followed by three more at four-week intervals, typically administered by a healthcare provider in a medical setting. Potential side effects include mild infusion reactions like hives, itching, rash, dizziness, and fatigue, which usually resolve on their own.

It is crucial to discuss Eptinezumab’s potential benefits and risks with your doctor to determine its appropriateness for your condition. They can guide you on managing side effects and monitor your response over time. If previous migraine treatments were ineffective, exploring Eptinezumab as an option is advisable. However, individual experiences with this therapy vary, and results may differ from person to person.

I hope I have addressed all your queries.

Take care. Thank you.